SBI-183 |
| Catalog No.GB40360 |
SBI-183 is an orally active inhibitor of QSOX1 (Kd value of 20 μM), thereby suppressing the proliferative and invasive phenotype of two renal cancer cell lines (786-O and RCJ-41T2), a triple negative breast cancer (TNBC) cell line (MDA-MB-231), a lung adenocarcinoma cell line (A549), and a pancreatic ductal adenocarcinoma (MIA PaCa2). Moreover, SBI-183 inhibits tumor growth in two independent human xenograft mouse models of renal cell carcinoma.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 625403-59-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
SBI-183 is an orally active inhibitor of QSOX1 (Kd value of 20 μM), thereby suppressing the proliferative and invasive phenotype of two renal cancer cell lines (786-O and RCJ-41T2), a triple negative breast cancer (TNBC) cell line (MDA-MB-231), a lung adenocarcinoma cell line (A549), and a pancreatic ductal adenocarcinoma (MIA PaCa2). Moreover, SBI-183 inhibits tumor growth in two independent human xenograft mouse models of renal cell carcinoma.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *